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Abstract. The long-term safety of budesonide/formoterol 
(BUD/FM) inhalation has not been fully evaluated, particu-
larly in elderly patients with bronchial asthma. To evaluate the 
12-month safety of BUD/FM inhalation for elderly asthmatic 
patients, the changes in serum potassium levels and pulse rate 
were examined. A retrospective chart review was conducted of 
consecutive patients who were treated with BUD/FM inhala-
tion (two inhalations of 160/4.5 mg, twice daily; Symbicort 
Turbuhaler, AstraZeneca) at a hospital between February 2010 
and January 2012. A total of 350 patients were treated with 
BUD/FM inhalation during the study period and were followed 
up over 12 months. The mean age of the patients was 60 years, 
and 19.4% and 21.4% of the patients were aged 65-74 years 
and ≥75 years, respectively. One hundred and fourteen 
(32.6%) of the 350 patients continued the inhalation therapy 
for >12 months. Compared with the pretreatment data, reduc-
tions in serum potassium levels at 1, 6 and 12 months were not 
observed, even in the patients aged 65-74 and ≥75 years. There 
was also no increase in the pulse rate at 1, 6 and 12 months, 
even in the patients aged 65-74 and ≥75 years. The usual 
dosage of BUD/FM showed no adverse effects on the serum 
potassium levels and pulse rate in the adults, including the 
elderly with persistent asthma.
Introduction
The use of an inhaled corticosteroid (ICS) and long-acting 
β2-agonist (LABA) combination inhaler is recommended 
by the Global Initiative for Asthma and most other asthma 
treatment guidelines as the first choice to control chronic 
asthma for patients in whom control with ICS monotherapy is 
difficult (1-4). Budesonide/formoterol (BUD/FM) inhalation 
aerosol is an ICS and LABA combination, which is admin-
istered twice daily via one hydrofluoroalkane-pressurized 
metered-dose inhaler and has been approved for use in many 
countries for the long-term maintenance treatment of persis-
tent asthma (2-4). With regard to safety, while the short-term 
safety in ICS (5-7) and ICS/LABA (8-10) has been evaluated, 
the long-term safety has yet to be fully investigated (11,12), 
particularly in elderly patients with bronchial asthma. In the 
present retrospective study, an evaluation of the 1-, 6- and 
12-month safety of BUD/FM inhalation for elderly asthmatic 
patients was performed, and the changes in serum potassium 
levels and pulse rate were observed.
Patients and methods
Patients. Clinicopathological data for all the patients with 
bronchial asthma were obtained by retrospective review from 
the database at the University of Tsukuba, Mito Medical Center, 
Mito Kyodo General Hospital (Mito, Japan). The consecutive 
patients who were diagnosed with bronchial asthma and 
treated with BUD/FM inhalation aerosol (two inhalations of 
160/4.5 mg, twice daily; Symbicort Turbuhaler; AstraZeneca, 
Osaka, Japan) between February 2010 and January 2012 at the 
hospital, were entered in this study. 
In order to evaluate the 1-year safety of BUD/FM inhala-
tion, a medical chart review of the patients up to January 2013 
was performed. Demographic data, including age, gender and 
comorbid diseases were retrieved from the patient medical 
records. This retrospective study conformed to the Ethical 
Guidelines for Clinical Studies issued by the Ministry of 
Health, Labor and Welfare of Japan.
Study population. The patient population was divided into 
three age groups: The <65 years group, the 65-74 years group 
and the ≥75 years group. The demographic data and safety of 
BUD/FM inhalation therapy were compared among the three 
age groups. Adverse effects were counted as they occurred 
during the study period. Blood samples were obtained from 
the patients in order to measure the serum potassium levels, 
and pulse rates were measured at pretreatment and 1, 6 and 
12 months following the initiation of the BUD/FM inhalation 
therapy. 
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Statistical analysis. The serum potassium levels and pulse rate 
prior to treatment and at 1, 6 and 12 months after treatment 
were compared using Wilcoxon rank sum test. To compare the 
different groups of patients, the chi-square test was also used. 
All statistical analysis were performed using SPSS software, 
version 10.1 for Windows (SPSS Inc., Chicago, IL, USA) and 
P<0.05 was considered to indicate a statistically significant 
difference. 
Results
Patient characteristics. Table I shows patient characteristics. 
A total of 350 patients with bronchial asthma were treated 
with BUD/FM inhalation during the study period. There were 
189 males and the median age was 60 years (range: 17-93 years). 
In total, 207 (59.2%) patients were aged <65 years, 68 (19.4%) 
patients were 65-74 years old and 75 (21.4%) patients were 
≥75 years old (Table I). Among the 350 patients, 160 (45.7%) 
patients had comorbid diseases, including cardiovascular 
diseases in 74 patients (54 patients had hypertension, 12 had 
chronic heart failure, six had arrhythmia and five had ischemic 
heart disease). Fifty-six patients (74.7%) aged ≥75 years had one 
or more comorbid diseases, and 64.7% and 24.1% of patients 
aged 65-74 years and <65 years had one or more comorbid 
diseases, respectively. There was a significant difference in the 
incidence of one or more comorbid diseases between patients 
aged ≥65 years and those aged <65 years (P=0.001; chi-square 
test). However, there was no difference in the incidence of 
comorbid diseases between patients aged ≥65-74 years and 
those aged <75 years (P=0.603; chi-square test).
Treatment of bronchial asthma. An effective control of 
bronchial asthma was obtained, so BUD/FM inhalation 
therapy in 141 (40.3%) of the 350 patients was terminated or 
changed to ICS inhalation within 3 months. Similarly, in 95 
(27.1%) patients, the inhalation therapy was terminated within 
3-12 months. Therefore, the inhalation therapy was continued 
for >12 months in 114 (32.6%) patients. 
Safety of BUD/FM inhalation 
Adverse events. Four (1.1%) patients exhibited hoarseness, and 
three of them were aged ≥75 years. Two (0.6%) patients devel-
oped a tremor and both were <75 years of age. Two (0.6%) 
patients had oral candidiasis and arrhythmia, and each of them 
was ≥75 years of age. All adverse events were transient and 
disappeared shortly after the termination of the inhalation 
therapy.
Serum potassium. Fig. 1 shows the changes in serum 
potassium levels between pretreatment and 1 month after the 
initiation of BUD/FM therapy. There was no statistical differ-
ence between them (P=0.567). As shown in Table II, serum 
potassium levels at 6 and 12 months were not different from the 
levels before treatment (P=0.941 and P=0.822, respectively). 
In the 65-74 years group and the ≥75 years group, serum potas-
sium levels at 1, 6 and 12 months was not different from the 
levels before treatment. The changes in serum potassium levels 
in patients with cardiovascular diseases, and those ≥75 years 
with comorbid diseases were also examined. There was no 
statistical differences between serum potassium levels at these 
intervals (Table II).
Pulse rate. Fig. 2 shows changes in pulse rate between 
pretreatment and 1 month after the initiation of BUD/FM 
therapy. The pulse rate 1 month after the initiation of BUD/FM 
therapy was significantly lower than the pulse rate prior to 
treatment (P=0.001). In the ≥75 years group, the pulse rate 
was also decreased at the 6-month interval (P=0.046); these 
results may be due to the achievement of control of bronchial 
asthma. However, there was no statistically significant differ-
ence in pulse rate between any other age groups or intervals 
(Table III). The change in pulse rate in asthmatic patients with 
cardiovascular diseases and those ≥75 years with comorbid 
diseases were also examined, and no statistical differences 
between any age groups and any intervals were identified 
(Table III).
Table I. Characteristics of 350 patients with bronchial asthma.
Variable Data
Age (years) 60 (17-93)a
  ≤65 207 (59.2%)
  65-74 68 (19.4%)
  ≥75 75 (21.4%)
Gender
  Male 189
  Female 161
Comorbid diseases
  Present 160 (45.7%)
Cardiovascular diseases 74
  Hypertension 54
  Chronic heart failure 12 
  Arrhythmia 6
  Ischemic heart disease 5
  Others 4
Respiratory diseases 43
  COPD 26
  Pneumonia 5
  Others 8
Metabolic diseases 43
  Diabetes 29
  Thyroid disease 5
  Others 9
Renal and urologic diseases 14
Autoimmune diseases 9
Psychiatric diseases 8
Malignant diseases 7
Other diseases 14
Other controllers
  Leukotriene antagonists 41
  Xanthines 19
  Oral steroids 2
COPD, chronic obstructive pulmonary disease. amedian with range 
in parentheses.
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Discussion
BUD, a potent and safe ICS with a high affinity for glucocorti-
coid receptors, is approved in many countries for the treatment 
of asthma (2-4). The addition of inhaled LABA provides a more 
effective means of improving lung function and asthma control 
than increasing the dose of ICS in patients whose asthma is not 
adequately controlled. FM is unique amongst LABAs as it has 
a fast onset of action and a long duration of effect (2,3). BUD 
and FM, as individual components and in combination, possess 
well-defined efficacy as well as pharmacological and safety 
profiles when administered through a single metered-dose 
inhaler (4,8-10). In the present study, an evaluation of safety 
over 12 months of the usual dose of BUD/FM was performed, 
and the serum potassium levels and pulse rate were examined 
in elderly patients with bronchial asthma. 
There has been increasing interest in the treatment of 
elderly patients with bronchial asthma (13). However, clinical 
information regarding asthmatic patients aged ≥75 years 
has been scarcely available as such patients are not usually 
included in clinical trials and retrospective care analysis. 
Therefore, there is scientific uncertainty regarding the risks 
and benefits of treatment with ICS/LABA in asthmatic 
patients aged ≥75 years. To assess the short-term efficacy and 
safety of the treatment in the elderly, we previously reviewed 
our clinical data from consecutive patients with bronchial 
asthma treated with BUD/FM (14). Even with the existence 
of comorbid diseases in the elderly, BUD/FM was effective 
with no high incidences of adverse events, such as hoarseness, 
tremor, arrhythmia and oral candidiasis (14). The incidences 
observed were similar to those reported in previous studies in 
young adults and middle-aged patients (8-10).
Table II. Change in serum potassium levels prior to and following BUD/FM inhalation.
 Pretreatment K level Post-treatment K level
Patients (median, range; mEq/l) (median, range; mEq/l) P-value
All patients
  1-month interval 4.1, 3.4-5.4 4.2, 3.1-5.3 0.567
  6-month interval 4.1, 3.4-5.0 4.1, 3.5-5.1 0.941
  12-month interval 4.2, 3.4-5.4 4.2, 3.5-5.2 0.822
Patients aged ≥65 years
  1-month interval 4.2, 3.5-5.4 4.2, 3.6-4.9 0.286
  6-month interval 4.2, 3.5-5.0 4.1, 3.6-5.1 0.457
  12-month interval 4.2, 3.4-5.4 4.3, 3.5-5.2 0.989
Patients aged ≥75 years
  1-month interval 4.2, 3.6-5.4 4.2, 3.6-4.9 0.691
  6-month interval 4.1, 3.6-5.0 4.1, 3.6-4.8 0.909
  12-month interval 4.1, 3.4-5.4 4.3, 3.5-5.0 0.472
Patients with cardiovascular diseases
  1-month interval 4.1, 3.4-4.9 4.3, 3.2-5.0 0.680
  6-month interval 4.1, 3.5-5.0 4.3, 3.6-5.1 0.345
  12-month interval 4.1, 3.0-5.0 4.2, 3.6-5.0 0.731
Patients ≥65 years with cardiovascular diseases 
  1-month interval 4.2, 3.7-4.9 4.3, 3.5-4.9 0.967
  6-month interval 4.3, 3.7-5.0 4.1, 3.6-5.1 0.795
  12-month interval 4.3, 3.7-5.0 4.3, 3.7-5.0 0.948
BUD/FM, budesonide/formoterol; K, potassium.
Figure 1. Serum potassium levels prior to and 1 month after the initiation 
of BUD/FM inhalation. No statistically significant difference was identified 
(P=0.567). BUD/FM, budesonide/formoterol.
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Previous studies have investigated the 1-year safety of the 
usual dosage of FM (5-7) and BUD/FM inhalation for asthma 
patients (8-10). In these studies, the mean age of the patients 
evaluated was ~30-40 years (8-10). Rosenhall et al evaluated 
the 1-year safety of BUD/FM (8), and Maspero et al examined 
mometasone furoate/FM (9), and they concluded that both treat-
ments were safe and well tolerated in patients with persistent 
asthma (8,9). However, in these studies, there was no investiga-
tion into the changes in serum potassium levels and pulse rate. 
With regard to the evaluation of these parameters, Hinkle et al 
studied heart rate in pediatric subjects with stable asthma (15), 
and Malolepszy et al examined serum potassium levels and 
heart rate in high-dose FM in patients with acute bronchial 
obstruction (16). Recently, Saito and Hasunuma studied the 
short-term safety of high dose BUD/FM in asthmatic patients, 
whose mean age was 44.3 years (11). In their study, >10% of 
patients showed palpitation, tachycardia and decreased serum 
potassium levels in a 2.5-fold higher dose of BUD/FM than 
the usual dose of therapy (11). In the present study, the median 
age of the patients was 60 years, and 40.8% and 21.4% of 
them were ≥65 and ≥75 years of age, respectively. Aging is 
associated with a high prevalence of comorbid diseases (13). 
Elderly patients are predisposed to comorbid diseases, such as 
diabetes, cardiovascular and cerebrovascular diseases. In the 
present study, the ≥65 years group had a higher proportion of 
patients with comorbid diseases than those <65 years of age. 
However, there were neither significant reductions in serum 
potassium levels nor changes in pulse rate in the three age 
groups, including those with comorbid diseases.
The results of the present study revealed novel findings; 
however, there were a number of limitations in this study. This 
was a small-sized retrospective study in a single institution. 
Serum potassium levels and pulse rate were not evaluated in 
every patient and a quality of life analysis was not performed 
in this study. Therefore, we consider that conclusive outcomes 
were not derived from this study. However, the methodology 
Figure 2. Pulse rate prior to and 1 month after the initiation of BUD/FM inha-
lation. The pulse rate 1 month after the BUD/FM inhalation was significantly 
lower than that after treatment (P=0.001). BUD/FM, budesonide/formoterol.
Table III. Change in pulse rates prior to and following BUD/FM inhalation.
 Pretreatment pulse rare Post-treatment pulse rate
Patients (median, range; bpm) (median, range; bpm) P-value
All patients
  1-month interval 80, 48-132 77, 46-110 0.001
  6-month interval 81, 48-120 80, 52-120 0.081
  12-month interval 80, 48-120 77, 50-109 0.050
Patients aged ≥65 years
  1-month interval 78, 54-110 77, 56-110 0.210
  6-month interval 81, 54-106 76, 56-105 0.163
  12-month interval 80, 54-106 76, 56-109 0.288
Patients aged ≥75 years
  1-month interval 81, 60-110 78, 58-110 0.093
  6-month interval 81, 60-106 76, 56-105 0.046
  12-month interval 81, 60-106 77, 56-109 0.128
Patients with cardiovascular diseases
  1-month interval 80, 52-120 79, 46-110 0.140
  6-month interval 80, 54-120 80, 56-120 0.915
  12-month interval 78, 60-120 77, 60-92 0.762
Patients aged ≥65 years with cardiovascular diseases
  1-month interval 81, 54-102 80, 56-97 0.325
  6-month interval 81, 54-102 80, 56-98 0.726
  12-month interval 80, 54-102 76, 58-92 0.807
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used, which was based on an audit of the information from 
clinical practice documented in the patient records, may 
provide some clinical information that was not available 
from clinical trials. Additionally, reporting the treatment 
experiences in patients with bronchial asthma, including those 
of elderly patients with some comorbid diseases, may be of 
clinical significance.
In conclusion, the usual dosage of BUD/FM (two inhala-
tions of 160/4.5 mg, twice daily) showed no adverse effects on 
the serum potassium levels and pulse rate in Japanese adults, 
including the elderly with persistent asthma.
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